Detalhe da pesquisa
1.
Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model.
Antimicrob Agents Chemother
; 58(7): 3843-52, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24752278
2.
In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
Antimicrob Agents Chemother
; 57(11): 5320-9, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23959304
3.
In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.
Antimicrob Agents Chemother
; 54(3): 1290-7, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20047911
4.
AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B.
PLoS One
; 10(12): e0144383, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26656974
5.
The T cell-selective IL-2 mutant AIC284 mediates protection in a rat model of Multiple Sclerosis.
J Neuroimmunol
; 282: 63-72, 2015 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25903730
6.
Inactivated ORF virus shows antifibrotic activity and inhibits human hepatitis B virus (HBV) and hepatitis C virus (HCV) replication in preclinical models.
PLoS One
; 8(9): e74605, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24066148
7.
Interleukin-4 impairs granzyme-mediated cytotoxicity of Simian virus 40 large tumor antigen-specific CTL in BALB/c mice.
Cancer Immunol Immunother
; 56(10): 1625-36, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17431618